Tetsuya Mitsudomi

17PUBLICATIONS
118CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsPeripheral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Jan 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Glenwood D Goss, Gail E Darling, Virginie Westeel

|Nov 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance.

Kenichi Suda, Yukihiro Yoshida, Hidenori Sato

|Mar 21, 2025
Sunvozertinib: shining light on lung cancer's exon 20 fight.

Tetsuya Mitsudomi

|Jan 08, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Mark M Awad, Patrick M Forde, Nicolas Girard

Pageof 3

Frequent Collaborators

4 joint publications

Shunichi Sugawara

3 joint publications

Nobuyuki Yamamoto

3 joint publications

Makoto Nishio

3 joint publications

Akihiko Gemma